UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for bladder cancer in the United Kingdom. Explore treatment pathways including immunotherapy, chemotherapy, and bladder-sparing approaches.
Bladder cancer affects ~10,200 people per year in the UK, making it the 10th most common cancer. It is more common in men and strongly linked to smoking. Non-muscle invasive bladder cancer (NMIBC, ~75%) is usually treated with local procedures, while muscle-invasive disease (MIBC) requires more intensive treatment.
NMIBC: TURBT (transurethral resection) ± intravesical BCG or chemotherapy. Recurrent NMIBC: nadofaragene firadenovec (gene therapy) or Pembrolizumab for BCG-unresponsive CIS. MIBC: neoadjuvant chemotherapy (gemcitabine + cisplatin or MVAC) followed by radical cystectomy (bladder removal) or chemoradiation (bladder-sparing). Metastatic: first-line immunotherapy (pembrolizumab or atezolizumab) for platinum-ineligible patients, or chemotherapy followed by avelumab maintenance.
Active UK trials include: antibody-drug conjugates (enfortumab vedotin, sacituximab govitecan), new immunotherapy combinations, bladder-sparing approaches with enhanced chemoradiation, targeted therapy for FGFR-altered tumours (erdafitinib), and liquid biopsy for early detection of recurrence.
Free AI-powered matching - no signup required
Search urothelial carcinoma Trials →